Physician profile

Abhinav Singla

Addiction Medicine (Internal Medicine) · Joliet, IL

NPI 1659300796

$115,390.43

in general payments reported to CMS, 2019-2025

79 companies · $6,843 in 2025

The $6,843 reported for 2025 was more than what 94% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$24,015.00
Food and Beverage$11,390.61
Education$216.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $57,305.22 2019-2025 Vraylar, Ubrelvy, Qulipta
Allergan, INC. $37,209.67 2019-2021
Novo Nordisk INC $1,552.69 2019-2025 Ozempic, Rybelsus, Wegovy
Otsuka America Pharmaceutical, INC. $1,461.09 2019-2025 Rexulti
Astrazeneca Pharmaceuticals LP $1,393.71 2019-2025 Airsupra, Breztri, Farxiga
Lilly USA, LLC $1,356.18 2019-2025 Mounjaro, Emgality, Jardiance
Teva Pharmaceuticals USA, INC. $1,241.18 2019-2025 Austedo Xr, Austedo Xr, Austedo
Nestle Healthcare Nutrition INC. $1,208.81 2020-2023
Pfizer INC. $985.29 2019-2025
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $885.50 2019-2025 Relistor, Xifaxan
Boehringer Ingelheim Pharmaceuticals, INC. $645.37 2019-2024 Jardiance, Synjardy, Tradjenta
Aimmune Therapeutics, INC. $621.51 2024-2025 Zenpep
Glaxosmithkline, LLC. $614.87 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Axsome Therapeutics, INC. $523.49 2023-2025 Symbravo, Auvelity, Sunosi
Takeda Pharmaceuticals U.S.A., INC. $477.80 2019-2025 Trintellix
Show all 79 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $460.91 2019-2024 Repatha, Otezla
Orexo US, INC. $416.38 2019-2025 Zubsolv
Upsher-Smith Laboratories LLC $334.80 2019-2022
Lundbeck LLC $309.70 2020-2025 Rexulti
Collegium Pharmaceutical, INC. $302.17 2019-2022
Janssen Pharmaceuticals, INC $274.37 2019-2022
Harmony Biosciences LLC $262.54 2023-2025 Wakix
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $254.68 2023-2025 Caplyta
Jazz Pharmaceuticals INC. $244.28 2019-2022
Biohaven Pharmaceutical Holding Company LTD. $240.42 2022
Kowa Pharmaceuticals America, INC. $234.76 2022-2024 Livalo, Seglentis
Phathom Pharmaceuticals, INC. $222.47 2024-2025 Voquezna
Currax Pharmaceuticals LLC $220.11 2019-2025 Contrave, Onzetra Xsail, Nexlizet
Alkermes, INC. $196.44 2019-2025 Aristada, Lybalvi
Almatica Pharma LLC $189.95 2020-2024 Loreev Xr
Antares Pharma, INC. $177.37 2019-2025 Xyosted, Nocdurna, Tlando
E.R. Squibb & Sons, L.L.C. $175.04 2020-2024 Eliquis
Amarin Pharma, INC. $166.81 2019-2022
Inspire Medical Systems, INC. $143.45 2025 Inspire
Braeburn INC. $139.79 2023-2025 Brixadi
Bayer Healthcare Pharmaceuticals INC. $139.58 2022-2024
Sk Life Science, INC. $137.24 2022-2024 Xcopri
Merck Sharp & Dohme LLC $133.01 2021-2023 Belsomra
Indivior INC. $130.51 2019-2024 Sublocade
Uswm, LLC $123.28 2021-2023 Zimhi, Lucemyra
Sanofi-Aventis U.S. LLC $115.39 2019-2021
Bausch Health US, LLC $111.65 2019-2022
Scilex Pharmaceuticals INC. $110.40 2019-2025
Amneal Pharmaceuticals LLC $108.30 2019-2022
Vivus LLC $102.46 2019-2025 Pancreaze
Novartis Pharmaceuticals Corporation $102.39 2022-2023
Ibsa Pharma INC. $100.81 2021-2022
Biodelivery Sciences International, INC. $100.16 2019-2021
Redhill Biopharma INC. $94.36 2020-2021
Vanda Pharmaceuticals INC. $89.64 2024-2025 Fanapt
Horizon Therapeutics Plc $73.10 2019-2021
Exact Sciences Corporation $70.88 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Idorsia Pharmaceuticals US INC $68.48 2023-2024 Quviviq
Arbor Pharmaceuticals, INC. $65.25 2019-2021
Corcept Therapeutics $63.90 2019
Eisai INC. $63.84 2019-2022
Astellas Pharma US INC $60.89 2019-2021
Xeris Pharmaceuticals, INC. $58.72 2021-2022
Impel Pharmaceuticals LLC $56.53 2024-2025 Trudhesa
Ethicon US, LLC $52.86 2019-2020
Hikma Pharmaceuticals USA $49.33 2019-2022
Sunovion Pharmaceuticals INC. $45.57 2019
Neuronetics, INC. $44.89 2019
Impel Pharmaceuticals INC. $44.21 2023 Trudhesa
Mdd US Operations, LLC $43.40 2019
Biohaven Pharmaceuticals, INC. $42.77 2021
Halozyme INC $40.10 2023
Abbott Laboratories $39.51 2023-2025 Freestyle Libre 3
Clarus Therapeutics INC. $36.15 2021
Adlon Therapeutics L.P. $32.27 2020-2021
Dexcom, INC. $30.45 2024 Dexcom G6 Transmitter
Philips North America LLC $29.99 2023
Boston Scientific Corporation $24.66 2024 Watchman Flx
Kaleo, INC. $21.13 2019
Shire North American Group INC $19.96 2019
Esperion Therapeutics, INC. $19.66 2022
Azurity Pharmaceuticals, INC. $17.06 2023 Horizant
Shionogi INC $14.39 2019
Assertio Therapeutics, INC. $12.48 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Abhinav Singla

$115,390.43

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $6,843 reported for 2025 was more than what 94% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).

https://glasscript.com/doctor/210122/abhinav-singla

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.